Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.

Authors :: Nooka, Ajay K.
Lesokhin, Alexander M.
Mohty, Mohamad
Niesvizky, Ruben
Maisel, Christopher
Arnulf, Bertrand
Larson, Sarah Marie
Varshavsky Yanovsky, Asya
Leleu, Xavier P
Karlin, Lionel
Vesole, David H.
Bahlis, Nizar J.
Fernández de Larrea, Carlos
Raje, Noopur S.
Leip, Eric
Conte, Umberto
Elmeliegy, Mohamed
Viqueira, Andrea
Manier, Salomon
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p8008-8008, 1p
Publication Year :: 2023

Full Text Access

Tools